Creso Pharma (ASX:CPH) primed to profit from potential changes to U.S. psychedelics laws

• Californian lawmakers are set to vote on a bill to legalise the possession of psychedelics in a major step forward for the United States' ongoing decriminalisation of recreational drugs
• The legislation would remove the penalties for the possession of psychedelic drugs like LSD, psilocybin mushrooms, MDMA and more
• If approved by the Senate, the bill will head to the Assembly after which it will potentially land on the Governor's desk
• ASX-listed Creso Pharma (CPH) is in a unique position to benefit from the fresh legislation with its focus on the psychedelic market
• The company's future subsidiary Halucenex develops and licences psychedelic compounds for the pharmaceutical and nutraceutical markets
• Further to this, Creso appointed John Griese as Director of U.S. Business Development in April to help the company solidify its place in the U.S. market
• With the global psychedelics market forecast to be worth US$10.75 billion (around A$13.9 billion) by 2027, Creso and Halucenex are taking proactive action to create an immediate path to revenue in the new market

Read the Full Article on The Market Herald here